{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T01:45:40Z","timestamp":1788659140213,"version":"build-2803163510"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Catharina Research Fund"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>As small\u2010bowel adenocarcinoma (SBA) is scarce, no standard systemic regimen in metastatic disease has been defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To obtain insights into the use and effects of palliative chemotherapy in patients with metastatic SBA in a population\u2010based setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from the Netherlands Cancer Registry of patients with metastatic SBA between 2007 and 2016 were used (<jats:italic>n<\/jats:italic>\u2009=\u2009522). For patients treated with palliative chemotherapy, differences in treatment regimens and survival were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Palliative chemotherapy was received by 38% of patients (<jats:italic>n<\/jats:italic>\u2009=\u2009199). First\u2010line combination chemotherapy was administered to 80% of patients, mainly CAPOX\/FOLFOX. Single\u2010agent chemotherapy mostly consisted of capecitabine. Second\u2010line treatment, mostly irinotecan\u2010based (58%), was prescribed to 27% of patients. Age 70 years or older was an adverse predictive factor for receiving first\u2010line combination chemotherapy (odds ratio (OR) 0.2, 95% confidence interval (CI) 0.08\u20130.62) and second\u2010line therapy (OR 0.3, 95% CI 0.10\u20130.72). Median overall survival with palliative chemotherapy was 9.3 months, compared with 3.0 months without. In subanalyses, patients who received only first\u2010line treatment had a median overall survival of 5.6 and 7.0 months after single\u2010agent and combination chemotherapy, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A minority of patients were treated with palliative chemotherapy. First\u2010line treatment consisted predominantly of oxaliplatin\u2010based combination chemotherapy, whereas second\u2010line treatment was mainly irinotecan\u2010based. Population\u2010based median overall survival for selected patients treated with chemotherapy amounted to nine months.<\/jats:p><\/jats:sec>","DOI":"10.1177\/2050640619858211","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T04:33:29Z","timestamp":1560573209000},"page":"1380-1388","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Palliative chemotherapy for patients with synchronous metastases of small\u2010bowel adenocarcinoma: A reflection of daily practice"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0305-391X","authenticated-orcid":false,"given":"Laura M","family":"Legu\u00e9","sequence":"first","affiliation":[{"name":"Department of Medical Oncology<!--<institution-id institution-id-type=\"Ringgold\">3168<\/institution-id>--> Catharina Hospital Eindhoven the Netherlands"},{"name":"Department of Research Netherlands Comprehensive Cancer Organisation Eindhoven the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke","family":"Bernards","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology<!--<institution-id institution-id-type=\"Ringgold\">3168<\/institution-id>--> Catharina Hospital Eindhoven the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery EPP","family":"Lemmens","sequence":"additional","affiliation":[{"name":"Department of Research Netherlands Comprehensive Cancer Organisation Eindhoven the Netherlands"},{"name":"Department of Public Health Erasmus MC University Medical Centre Rotterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace HJT","family":"de Hingh","sequence":"additional","affiliation":[{"name":"Department of Research Netherlands Comprehensive Cancer Organisation Eindhoven the Netherlands"},{"name":"Department of Surgical Oncology<!--<institution-id institution-id-type=\"Ringgold\">3168<\/institution-id>--> Catharina Hospital Eindhoven the Netherlands"},{"name":"GROW School for Oncology and Developmental Biology Maastricht University Maastricht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert-Jan","family":"Creemers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology<!--<institution-id institution-id-type=\"Ringgold\">3168<\/institution-id>--> Catharina Hospital Eindhoven the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice N","family":"van Erning","sequence":"additional","affiliation":[{"name":"Department of Research Netherlands Comprehensive Cancer Organisation Eindhoven the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,12]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.04.013"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20404"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2016.1182211"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq038"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1138-6"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30766"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.7145"},{"key":"e_1_2_11_9_2","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.7150\/jca.16606","article-title":"A retrospective review of chemotherapy for patients with small bowel adenocarcinoma in British Columbia","volume":"7","author":"Duerr D","year":"2016","journal-title":"J Cancer"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01. coc.0000214931.01062.01"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-2-132"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-205"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23822"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0079"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e328350dd0d"},{"key":"e_1_2_11_16_2","first-page":"689","article-title":"Efficacy of the FOLFOX\/CAPOX regimen for advanced small bowel adenocarcinoma: A three-center study from China","volume":"16","author":"Zhang L","year":"2011","journal-title":"J BUON"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2017.09.123"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235"},{"key":"e_1_2_11_19_2","first-page":"CD004064","article-title":"Chemotherapy for advanced gastric cancer","volume":"8","author":"Wagner AD","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9378"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073149"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1051"},{"key":"e_1_2_11_23_2","first-page":"31","article-title":"Oxaliplatine als eerstelijnsbehandeling van het gemetastaseerde colorectaal carcinoom","volume":"4","author":"NVMO-commissie Beoordeling van Oncologische Middelen (BOM)","year":"2001","journal-title":"Medische Oncologie"},{"key":"e_1_2_11_24_2","first-page":"29","article-title":"5FU-precursor capecitabine bij het gemetastaseerde colorectaal carcinoom","volume":"4","author":"NVMO-commissie BOM","year":"2001","journal-title":"Medische Oncologie"},{"key":"e_1_2_11_25_2","first-page":"32","article-title":"Toevoeging van irinotecan aan eerstelijns behandeling van gemetastaseerd colorectaal carcinoom","volume":"4","author":"Willemse P","year":"2001","journal-title":"Medische Oncologie"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205853"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.037"},{"key":"e_1_2_11_28_2","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1080\/02841860701261568","article-title":"Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer","volume":"46","author":"S\u00f8rbye H","year":"2007","journal-title":"Acta Oncol"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25614"},{"key":"e_1_2_11_30_2","first-page":"23","article-title":"Irinotecan als tweedelijns therapie voor pati\u00ebnten met voortgeschreden colorectaal carcinoom","volume":"3","author":"Zonnenberg B","year":"2000","journal-title":"Medische Oncologie"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02034-1"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.113"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135673"},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt401"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640619858211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1177\/2050640619858211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640619858211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T06:33:10Z","timestamp":1693722790000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1177\/2050640619858211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1177\/2050640619858211"],"URL":"https:\/\/doi.org\/10.1177\/2050640619858211","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}